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Neuroimaging genetics is an emerging field that aims to identify the associations between genetic 
variants (e.g., single nucleotide polymorphisms (SNPs)) and quantitative traits (QTs) such as brain 
imaging phenotypes. In recent studies, in order to detect complex multi-SNP-multi-QT associations, 
bi-multivariate techniques such as various structured sparse canonical correlation analysis (SCCA) 
algorithms have been proposed and used in imaging genetics studies. However, associations between 
genetic markers and imaging QTs identified by existing bi-multivariate methods may not be all disease 
specific. To bridge this gap, we propose an analytical framework, based on three-way sparse canonical 
correlation analysis (T-SCCA), to explore the intrinsic associations among genetic markers, imaging 
QTs, and clinical scores of interest. We perform an empirical study using the Alzheimer’s Disease 
Neuroimaging Initiative (ADNI) cohort to discover the relationships among SNPs from AD risk gene 
APOE, imaging QTs extracted from structural magnetic resonance imaging scans, and cognitive and 
diagnostic outcomes. The proposed T-SCCA model not only outperforms the traditional SCCA method 
in terms of identifying strong associations, but also discovers robust outcome-relevant imaging genetic 
patterns, demonstrating its promise for improving disease-related mechanistic understanding.
Alzheimer’s disease (AD) is the most common form of dementia characterized by progressive impairment of 
memory and other cognitive functions in people over 65 years of age1. It is an important research topic to develop 
methods for early diagnosis of AD. At present, many studies have focused on searching for biomarkers from brain 
imaging data as well as molecular and cellular data to investigate the pathological changes2. To further aid the 
development of effective diagnostic and therapeutic approaches, it has received increasing attention to study AD 
at the system biology level. For example, revealing the biological pathway from the microcosmic genetic factors to 
macroscopic brain anatomy has the potential to understand pathogenicity mechanisms underlying the disordered 
cognition and behavior.
Enabled by recent advances in high-throughput genotyping and multimodal neuroimaging technologies, 
imaging genetics is becoming an emerging research field for discovering the associations between genetic mark-
ers such as single nucleotide polymorphisms (SNPs) and quantitative traits (QTs) extracted from structural or 
functional neuroimaging data3,4. Thus, it holds great promise for us to understand the complex neurogenetic and 
neurobiological mechanism of complex brain disorders5.
In prior imaging genetics studies, univariate and multivariate regression methods have been typically used 
to capture the effective associations between SNPs and neuroimaging data6–10. More recently, bi-multivariate 
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analysis techniques such as various structured sparse canonical correlation analysis (SCCA) models have 
attracted increasing attention in brain imaging genetics to detect complex multi-SNP-multi-QT associations11–18. 
The essence of all the structured SCCA approaches, incorporating valuable prior knowledge, is to find the best 
linear transformations for imaging and genetic features respectively so that the strongest correlation between 
the imaging and genetic components can be achieved. These methods have the potential to discover effective 
imaging genetic associations, while the identified genotypic and phenotypic markers may not be disease specific. 
To overcome this limitation, in this paper, we focus on exploring three-way associations among genetic markers, 
imaging QTs, and cognitive and diagnostic outcomes. Our goal is to reveal the relationships among these mul-
tidimensional genetics, imaging and outcome data, and contribute to a better understanding of pathogenicity 
mechanisms in AD.
Of note, some diagnosis information guided methods have been proposed in the field of imaging genetics. 
The sRRR model proposed in19,20 used a two-step procedure for detecting genetic factors associated with disease 
relevant imaging phenotypes by using penalized linear discriminant analysis. More recently, a Bayesian frame-
work was used to select the relevant features along the pathway from gene to imaging and then to symptom21. It is 
worth noting that both models treated diagnosis information as binary status (e.g., AD and normal control (NC)) 
for imaging genetic association studies. Actually, in the spectrum between NC and AD, there exist other progres-
sive stages. For example, in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) study, there were partici-
pant groups labeled as Significant Memory Concern (SMC), Early Mild Cognitive Impairment (EMCI) and Late 
Mild Cognitive Impairment (LMCI). In addition, the cognitive scores such as Mini-Mental State Examination 
(MMSE), Clinical Dementia Rating (CDR), ADNI Memory (ADNI-MEM) and ADNI Executive Functioning 
(ADNI-EF), which are neuropsychological assessment measures from different aspects, are often used as quanti-
tative descriptions of symptom severity instead of binary diagnosis. Accordingly, identification of imaging genetic 
associations relevant to these diagnostic and cognitive outcomes may yield important information for a better 
understanding of disease-specific mechanisms.
With these observations, we consider the outcome-relevant imaging genetic association study as a multi-view 
multivariate correlation problem, which can be solved by CCA and partial least squares (PLS), as well as their 
sparse versions (including SCCA and SPLS)11–13,22,23. Thus, following the existing imaging genetic studies via 
bi-multivariate SCCA11, we propose a three-way sparse canonical correlation analysis (T-SCCA) framework to 
explore the intrinsic associations among SNP loci, neuroimaging features and clinical score outcomes. Specifically, 
in this study, the outcomes of interest include cognitive scores (CS) and diagnosis status (DS). We evaluate the 
effectiveness of the proposed method by identifying three-way associations among 85 candidate SNPs from the 
top AD risk gene APOE, 116 imaging QTs extracted from structural magnetic resonance imaging (MRI) scans, 
and relevant cognitive and diagnostic outcomes, using the Alzheimer’s Disease Neuroimaging Initiative (ADNI) 
data as a test bed. The experimental results demonstrate that the proposed T-SCCA model not only outper-
forms the standard two-way SCCA method in terms of identifying strong associations, but also discovers robust 
outcome-relevant imaging genetic patterns, demonstrating its promise for improving disease-related mechanistic 
understanding.
Imaging genetic associations
Imaging genetic associations via bi-multivariate analysis. We first describe relevant notation. We 
use lowercase letters to denote vectors, and uppercase letters to denote matrices. For a given matrix = 

M mj
i , we 
denote its i-th row and j-th column as mi and mj respectively. Let X= [x1,… ,xn]T ∈ Rn×p be the SNP genotype data, 
Y = [y1, … , yn]T ∈ Rn×q be the imaging QT data (i.e., voxel-based morphometry measures in this work), where n is 
the number of participants, and p and q are the number of SNPs and QTs, respectively.
For detecting complex multi-SNP-multi-QT associations, sparse canonical correlation analysis (SCCA)11–13 
seeks linear transformations of variables X and Y to achieve the maximal correlation between Xw1 and Yw2 by 
introducing penalty terms simultaneously, which can be formulated as:
. . ≤ ≤ ≤ ≤
w X Yw
s t w X Xw w Y Yw w c w c
max
1, 1, , (1)
w w
T T
T T T T
,
1 2
1 1 2 2 1 1 1 2 1 2
1 2
where w1 and w2 are canonical loadings or weights, reflecting the contribution of each feature in the identified 
canonical correlation. Note that ≤ ≤w X Xw w Y Yw1, 1T T T T1 1 2 2  are used to embrace the covariance structure of 
the data in the model. ≤ ≤w c w c,1 1 1 2 1 2 are constraints for controlling the sparsity so that only a small number of relevant features will be selected automatically from the SNP and imaging data.
Cognitive score (CS)-relevant imaging genetic associations via three-way SCCA. In this study, 
for revealing the biological mechanism specific to the disease, we aim to discover imaging genetic associations that 
are relevant to cognitive scores (CSs) or diagnosis status. The first attempt focuses on involving multi-assessment 
CSs (i.e., MMSE, CDR, ADNI-MEM and ADNI-EF). Let Z = [z1, … , zn]T ∈ Rn×r be the CSs, where n is the number 
of participants, r is the number of CSs. Since different CSs can provide complementary perspectives on neuropsy-
chological assessments, we aim to seek a set of linear transforms to estimate the contribution of each individual 
cognitive score in imaging genetic associations.
The formulation of CS-relevant imaging genetic associations can be extended from eq. (1) as follows:
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where w3 is the canonical loading, reflecting the contribution of each neuropsychological assessment in the iden-
tified canonical correlation. Similar to the existing constraints in eq. (1), ≤w Z Zw 1T T3 3  is a newly added con-
straint to embrace the covariance structure, and ≤w c3 1 3 is another newly added constraint for selecting a small number of CS that are related to both imaging and genetics measures.
Diagnosis status (DS)-relevant imaging genetic associations via three-way SCCA. Besides the 
CSs, the diagnosis status (DS) considered as a qualitative measurement can also describe the progressive stages 
of AD. Accordingly, we propose another outcome-relevant imaging genetic association that involves DS. Let 
Z ∈ Rn×1 be the DS labels for all participants. The DS-relevant formulation, similar to eq. (2), can be used for min-
ing DS-relevant imaging genetic associations.
It is worth noting that the equation of DS-relevant imaging genetic association is a special case of eq. (2) if 
r = 1. Similar to eq. (2), w3 is the canonical loading reflecting the contribution of DS in the identified canonical 
correlation, so that the optimization of w1,w2 and w3 can be also solved by the proposed algorithm.
Results
Characteristics of the dataset. The dataset comprises of 913 non-Hispanic Caucasian participants, 
including 211 normal control (NC), 82 significant memory concern (SMC), 273 early mild cognitive impairment 
(EMCI), 187 late mild cognitive impairment (LMCI) and 160 AD. In our experiments, we used the baseline 
structural MRI data with average voxel-based morphometry (VBM) measures in 116 regions of interest (ROIs), 
genotyping data with 85 candidate SNP loci, as well as cognitive scores (including MMSE, CDR, ADNI-MEM and 
ADNI-EF) and diagnosis status (including NC, SMC EMCI, LMCI and AD). For more details about the demo-
graphics and data processing, please see the complete information in the Methods section.
Experimental settings. In this imaging genetic association study, 5-fold cross-validation strategy is adopted 
to evaluate the effectiveness of our proposed method. For parameters of regularization, we determine their values 
by another nested 5-fold cross-validation on the training set. It is used to fine tune the parameters in the objective 
function in the range of {10−3, 3 × 10−3, 10−2, 3 × 10−2, 10−1, 3 × 10−1, 1, 3, 10, 30, 100}. The parameters yielding 
the best performance in the inner cross-validation are finally used in the resulting model.
In the current experiments, we compare BM-SCCA (denoting conventional bi-multivariate SCCA), CS-SCCA 
(denoting cognitive scores-guided method via three-way SCCA), DS-SCCA (denoting diagnosis-guided method 
via three-way SCCA). Both CS-SCCA and DS-SCCA belong to the T-SCCA category.
Improved association between risk SNPs and phenotypic imaging markers. We compare our 
proposed T-SCCA methods (including CS-SCCA and DS-SCCA) with the conventional method (BM-SCCA). 
The performance on each dataset is assessed using the correlation coefficient (CC) between SNP and imaging 
data, which is widely used for association analysis measurements. The average results of CC across the 5-fold 
training and testing data are calculated respectively. As shown in Table 1 and Table 2, CS-SCCA and DS-SCCA 
yield the CC values of 0.2633 (0.3667) and 0.2711 (0.3723) on test (training) set, respectively, which are better 
than those of BM-SCCA. These results indicate that the search space of BM-SCCA could be too large such that the 
algorithm could converge to local optima without prior knowledge, while the regularizations of the restrictions 
Method
Correlation Coefficient on Training Set
F1 F2 F3 F4 F5 Mean + Std
BM-SCCA 0.2619 0.2810 0.1846 0.2679 0.2755 0.2542 ± 0.0396
CS-SCCA 0.3436 0.3819 0.3743 0.3536 0.3798 0.3667 ± 0.0171
DS-SCCA 0.3519 0.3843 0.3848 0.3584 0.3822 0.3723 ± 0.0159
Table 1.  5-fold cross-validation results on ADNI: The model learned from the training data is used to 
estimate the correlation coefficients on the training set.
Method
Correlation Coefficient on Test Set
F1 F2 F3 F4 F5 Mean + Std
BM-SCCA 0.1996 0.1848 − 0.0250 0.2845 0.2320 0.1752 ± 0.1183
CS-SCCA 0.3328 0.2126 0.2258 0.3275 0.2180 0.2633 ± 0.0612
DS-SCCA 0.3566 0.2173 0.2200 0.3139 0.2474 0.2711 ± 0.0616
Table 2.  5-fold cross-validation results on ADNI: The model learned from the training data is used to 
estimate the correlation coefficients on the testing set.
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on outcome-relevant information might be able to guide imaging genetic associations out of over-fitting. This 
demonstrates the disease information could help improve the performances of correlations between genotypes 
and imaging phenotypes.
In addition, we perform a permutation test using 1000 permutations with retraining each of BM-SCCA, 
SC-SCCA and DS-SCCA models to assess the statistical significance of the identified correlations on the test 
set. The p-value corresponds to the fraction of times that the correlation coefficient is greater or equal to the 
result from original data. The resulting p-values (p < 0.001) are statistically significant in all three cases, including 
BM-SCCA, CS-SCCA and DS-SCCA, respectively.
Besides improving correlation performances, one major goal of this study is to identify genotypic and phe-
notypic markers that are not only highly correlated to each other, but also relevant to cognitive or diagnostic 
outcomes specific to AD. Figure 1 shows the heat map of average estimated canonical loadings on 85 APOE SNPs 
and 116 brain ROIs by BM-SCCA, CS-SCCA and DS-SCCA, respectively. The weighted colors of selected SNPs 
and brain regions presented by canonical loadings indicate the contributions of the corresponding genetic and 
phenotypic markers.
Figure 1. Heat map of average estimated canonical loadings on 85 APOE SNPs associated with 116 brain 
ROIs across 5-fold cross-validation respect to different methods. 
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Discussion
As expected, the well-known locus rs429358 is identified to be associated with gray matter loss in multiple 
AD-relevant ROIs, which is in accordance with the previous studies24. The C allele increases the risk of AD in 
APOE e4, which is encoded by rs429358 (www.snpedia.com/index.php/APOE) (www.alzgene.org)25. BM-SCCA 
seems to yield other loci such as rs405697 (this genetic variant in APOE region has shown only to be associated 
with human longevity in the literature26) and rs157594.
For the phenotype identifications, besides the well-known AD-related ROI left hippocampus, signals in the 
cerebellum and vermis areas are detected by BM-SCCA. However, the morphometric changes of the cerebel-
lum have not been widely validated as AD biomarkers. On the other hand, a few additional ROIs such as right 
amygdala, right calcarine, right cuneus, left and right frontal-sup-medial gyrus, right parahippocampal gurus 
have been detected as top 10 features associated with the risk genotype biomarker rs429358 by the proposed 
T-SCCA (including CS-SCCA and DS-SCCA). It’s worth noting that CS-SCCA captures similar patterns on brain 
imaging as DS-SCCA does for the most part. More interestingly, the same ROIs selected simultaneously by two 
types of T-SCCA have similar weight values, which demonstrates the robust and consistent biomarker findings. 
Note that these weights have different signs, which are caused by the negative directionality of the cognitive 
score values in relation to the diagnosis values. The top 10 selected MRI-VBM imaging features, as well as their 
averaged estimated canonical loadings generated by T-SCCA (combination of SC-SCCA and DS-SCCA) across 5 
cross-validation trials, are visualized in Fig. 2 by mapping them onto the human brain. The colors of the selected 
brain regions indicate the canonical loadings of the corresponding markers. The identified regions have potential 
clinical correlates in typical clinically well-described AD impairments. To our knowledge, the hippocampus is one 
of the first regions of the brain to suffer damage including memory loss and disorientation. In addition, amyg-
dala atrophy is related to aberrant motor behavior, with potential relationships to anxiety and irritability24. Some 
existing results suggest that the magnitude of amygdala atrophy is comparable to that of the hippocampus in the 
earliest clinical stages of AD27. The analytical result reassures that our method identifies a well-known correlation 
between genotypes and phenotypes that is severely and consistently affected by pathology in AD. Besides con-
firming the prior findings, our method also yields the associations between APOE rs429538 and other eminent 
AD markers such as both left and right frontal-sup-medial gyrus. There also appear to be specific relationships 
among genotypes, phenotypes and neuropsychiatric symptoms that deserve further investigation.
As mentioned earlier, the quantitative CSs (MMSE, CDR, ADNI-MEM and ADNI-EF) used to index cogni-
tive decline for disease severity are able to show the graded differences in participants, and we induce the sparsity 
constraint for selecting the related CSs in this imaging genetic associations study. The CS-SCCA yields the load-
ing values of 0.0095, − 0.0103, 0.0238, and − 0.0026 on MMSE, CDR, ADNI-MEM and ADNI-EF, respectively. 
Figure 2. Visualization of mapping top 10 average estimated canonical loadings generated by T-SCCA 
(combination of CS-SCCA and DS-SCCA) onto the brain. 
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It demonstrates ADNI-MEM is the top-ranked score that contributes to the multiple associations among gene, 
neuroimaging and cognition. Since all CSs are neuropsychological assessment measures from different aspects, 
the CS-SCCA provides a simple evaluating approach to investigate the relative contribution of each clinical score.
In summary, we have performed a neuroimaging genetics study for Alzheimer’s disease (AD) to explore 
the relationship between genetic variations in the APOE gene and brain ROIs measured by voxel based mor-
phometry (VBM). Various existing sparse canonical correlation analysis (SCCA) methods are only designed 
for bi-multivariate analysis, and often yield suboptimal results without considering the cognitive or diagnos-
tic outcomes. With these observations, we have investigated a three-way sparse canonical correlation analysis 
(T-SCCA) framework to discover the multiple associations among SNP loci, neuroimaging features and pheno-
typic outcomes (including cognitive scores (CSs) and diagnosis status (DS)). The experimental results performed 
on 913 subjects from ADNI show that our proposed T-SCCA model can substantially achieve higher correla-
tions between genotypic and phenotypic features. Specifically, besides the improved correlation performances, 
CS-SCCA captures similar patterns on canonical loadings as DS-SCCA. This supports the benefit of our general 
T-SCCA model that can also identify some significant and robust biomarkers in imaging genetic associations, 
revealing disease-specific patterns on the complex mechanisms. However, there could be different mechanisms 
leading to three-way associations between genetics, imaging and diagnosis. For example, on top of possible path-
way from genetics to imaging and then to disease, part of the genetic influences on disease might not be mediated 
through features captured by neuroimaging. In addition, genetics might independently affect disease suscepti-
bility and imaging features, resulting in association between imaging and diagnosis, or there might be hidden or 
confounding variables that drive these associations. Thus, it warrants further investigation to reveal the underly-
ing mechanisms related to the three-way associations discovered by our proposed T-SCCA methods.
In this initial study, where the number of samples exceeds the number of total features, the T-SCCA model 
can be successfully applied for association discovery coupled with feature selection. However, if the dataset has 
more features than samples, this ill-conditioned problem can be addressed via dimensionality reduction or regu-
larization. In particular, when the datasets contain far more features (e.g., SNPs at the genome-wide magnitude), 
it will greatly increase the computational complexity and memory requirement. Note that the normal equation 
in the optimization contains matrix inversion operations (the time complexity is O(n3), where n is the number of 
features). Therefore, it is an interesting future topic to develop a more efficient solution for our proposed T-SCCA 
and to identify potential markers from high-throughput genome-wide variants and neuroimaging quantitative 
traits in outcome-relevant imaging genetic studies.
In addition, in this study, we have explored the imaging genetic associations within a single population of 
non-Hispanic Caucasians. However, the effect of population structure is another important topic, and it may 
affect the identifications in multivariate associations due to the potential bias introduced by multiple populations 
in a study. In this case, the population structure adjustment should be considered in the study.
Methods
Subjects. Data used in the preparation of this study were obtained from the Alzheimer’s Disease 
Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). The ADNI was launched in 2003 as a public-pri-
vate partnership by several organizations, including the National Institute on Aging (NIA), the National Institute 
of Biomedical Imaging and Bioengineering (NIBIB), the Food and Drug Administration (FDA), private phar-
maceutical companies, and non-profit organizations. The primary goal of ADNI has been to test whether serial 
magnetic resonance imaging (MRI), positron emission tomography (PET), other biological markers, and clinical 
and neuropsychological assessment can be combined to measure the progression of mild cognitive impairment 
(MCI) and early Alzheimer’s disease (AD). The study protocols were approved by the institutional review boards 
of all participating centers (Nanjing University of Aeronautics and Astronautics, Northwestern Polytechnical 
University, Indiana University and ADNI (A complete list of ADNI sites is available at http://www.adni-info.
org/.)) and written informed consent was obtained from all participants or authorized representatives. All the 
analytical methods were performed on the de-identified ADNI data, and were determined by Indiana University 
Human Subjects Office as IU IRB Review Not Required. In addition, these methods were carried out in accord-
ance with the approved guidelines.
Participants were screened and enrolled according to criteria demonstrated in ADNI study protocol (http://
adni-info.org/Scientists/ADNIStudyProcedures.html#). The general inclusion/exclusion criteria of the subjects 
from ADNI procedures manual (http://www.adni-info.org) are briefly described as follows:
1. NC participants have no subjective or informant-based complaint of memory decline and normal cognitive 
performance. The MMSE scores on NC should be between 24 and 30, CDR should be 0.
2. SMC participants have subjective memory concerns as assessed using the Cognitive Change Index (CCI; 
total score from first 12 items > 16), no informant-based complaint of memory impairment or decline, and 
normal cognitive performance on the Wechsler Logical Memory Delayed Recall (LM-delayed) and the 
MMSE28.
3. EMCI participants have a memory concern reported by the subject, informant, clinician, abnormal memo-
ry function approximately 1 standard deviation below normative performance adjusted for education level 
on the LM-delayed, an MMSE total score greater than 24.
4. Besides a subjective memory concern as reported by subject, study partner or clinician, CDR on LMCI sub-
jects is 0.5 and Memory Box (MB) score must be at least 0.5.
5. MMSE score on AD should be between 20 and 26, and CDR should be 0.5 or 1.0.
In the practical diagnosis of AD, multiple clinical variables are generally acquired, e.g., MMSE, CDR, 
ADNI-MEM (composite score for memory) and ADNI-EF (composite score for executive functioning), etc. 
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Specifically, MMSE is used to examine functions including registration, attention and calculation, recall, language, 
ability to follow simple commands and orientation29,30. CDR is a numeric scale used to assess a patient’s cognitive 
and functional performance in six areas: memory, orientation, problem solving, community affairs, hobbies and per-
sonal care31. There are two derived composite scores for MEM and EF from ADNI. The formation of ADNI-MEM is 
complicated by the use of different word lists in the Rey Auditory Verbal Learning Test (RAVLT) and the ADAS-Cog, 
and by Logical Memory I data missing by design32. The formation of ADNI-EF includes Category Fluency-animals, 
Category Fluency-vegetables, Trails A and B, Digit span backwards, WAIS-R Digit Symbol Substitution, and 5 Clock 
Drawing items (circle, symbol, numbers, hands, time)33. The demographic information is summarized in Table 3.
SNP genotype data. Since genetic risk factors can help scientists focus on relevant biological pathways 
and form effective hypothesis for drug design, identifying risk genetic markers associated with brain imaging 
can help understand the underlying biological mechanisms. We downloaded the ADNI-GO/2 genotyping data, 
and performed quality control and population stratification using the approach described in the previous study34. 
To limit potential effects of population stratification, this study is focused only on analyzing non-Hispanic white 
participants. As the best-known genetic risk factor in AD, APOE (located on chromosome 19) has a key role in 
coordinating the mobilization and redistribution of cholesterol, phospholipids, and fatty acids, and it is impli-
cated in mechanisms such as neuronal development, brain plasticity, and repair functions35. Thus, we focused our 
analysis on all SNPs within ± 20 k base pairs of the APOE gene boundary based on the ANNOVAR (http://anno-
var.openbioinformatics.org) annotation, which include a total number of 85 SNPs as candidates. For the input in 
the models, each SNP value was coded in an additive fashion as 0, 1 or 2, indicating the number of minor alleles.
Imaging phenotype data. The MRI data used in this paper were also obtained from the ADNI database. 
We aligned the preprocessed imaging data (i.e., voxel based morphometry (VBM)) to each participant’s same 
visit scan, and then created normalized gray matter density maps from the MRI data in the standard Montreal 
Neurological Institute (MNI) space as 2 × 2 × 2 mm3 voxels SPM software package36. 116 ROI level measurements 
of mean gray matter densities were further extracted based on the MarsBaR AAL atlas37. All measurements were 
pre-adjusted for age, gender, and education.
Objective function and algorithm design. In this section, we design an algorithm to solve the optimi-
zation problem defined in eq. (2). For the general formulation, using the Lagrange multiplier and writing the 
penalties into the matrix form, the objective function for mining CS-relevant or DS-relevant imaging genetic 
associations via three-way sparse canonical correlation analysis (T-SCCA) is as follows:
β β β
= − − − + +
+ + + +
L w w w w X Yw w X Zw w Y Zw Xw Yw
Zw w w w
( , , ) 1
2
1
2
1
2 (3)
T T T T T T
1 2 3 1 2 1 3 2 3 1 2
2
2 2
2
3 2
2
1 1 1 2 2 1 3 3 1
where (β1, β2, β3) and are the set of model parameters. Take the derivative regarding w1, w2 and w3 separately and 
let them be zero:
β= + +−w X X D X Yw Zw( ) ( ) (4)T T1 1 1
1
2 3
β= + +−w Y Y D Y Xw Zw( ) ( ) (5)T T2 2 2
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where D1 is a diagonal matrix with the k1-th element as ∈
|| ||
k p( [1, ])
w
1
2 1k1 1 1
, D2 is a diagonal matrix with the k2-th 
element as ∈
|| ||
k q( [1, ])
w
1
2 2k2 2 1
, and D3 is a diagonal matrix with the k3-th element as ∈
|| ||
k r( [1, ])
w
1
2 3k3 3 1
.
Subjects NC SMC EMCI LMCI AD
Number 211 82 273 187 160
Gender(M/F) 109/102 33/49 153/120 108/79 95/65
Age 76.14 ± 6.53 72.45 ± 5.67 71.48 ± 7.12 73.86 ± 8.44 75.18 ± 7.88
Education 16.45 ± 2.62 16.78 ± 2.67 16.08 ± 2.62 16.38 ± 2.81 15.86 ± 2.75
MMSE 29.01 ± 1.23 29.00 ± 1.22 28.38 ± 1.54 27.71 ± 1.73 24.00 ± 2.62
CDR 0.01 ± 0.07 0.00 ± 0.00 0.49 ± 0.08 0.49 ± 0.07 0.72 ± 0.27
ADNI-MEM 1.02 ± 0.58 1.12 ± 0.57 0.60 ± 0.60 0.07 ± 0.67 − 0.76 ± 0.61
ADNI-EF 0.85 ± 0.69 0.73 ± 0.81 0.51 ± 0.74 0.18 ± 0.81 − 0.53 ± 0.91
Table 3.  Characteristics of the subjects. Note: NC = Normal Control, SMC = Significant Memory Concern, 
ECMI = Early Mild Cognitive Impairment, LCMI = Late Mild Cognitive Impairment, AD = Alzheimer’s disease.
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Since D1 relies on w1, D2 relies on w2, and D3 relies on w3, we introduce an iterative procedure to solve this 
objective. In each iteration, we first fix w2 and w3 to solve w1, then fix w1 and w3 to solve w2, and finally fix w1 and 
w2 to solve w3. The procedure stops until it satisfies a predefined stopping criterion. Algorithm 1 shows the pseudo 
code of the T-SCCA algorithm for mining outcome-relevant imaging genetic associations.
Algorithm 1: T-SCCA for Mining Outcome-relevant Imaging Genetic Associations
Input: candidate SNPs X =  [x1,… , xn]T∈ Rn×p,
    neuroimaging ROIs Y= [y1,… , yn]T∈ Rn×q,
    cognitive scores (CS) Z= [z1,… , zn]T∈ Rn×r or diagnosis status (DS) (r= 1 for Z)
Ensure: canonical vectors w1,w2,w3
Initialization: w1∈ Rp×1,w2∈ Rq×1,w3∈ Rr×1
While not converged regarding to w1,w2,w3 do
    
Calculate the diagonal matrix D1, where the k1-th element is || ||w k
1
2 1 1 1
;
    Update w1= (XTX+ β1D1)−1XT(Yw2+ Zw3);
    Scale w1 so that =Xw 11 2 ;
    Calculate the diagonal matrix D2, where the k2-th element is || ||w k
1
2 2 2 1
;
    Update w2= (YTY+ β2D2)−1YT(Xw1+ Zw3);
    Scale w2 so that =Yw 12 2 ;
    Calculate the diagonal matrix D3, where the k3-th element is || ||w k
1
2 3 3 1
;
    Update w3= (ZTZ+ β3D3)−1ZT(Xw1+ Yw2);
    Scale w3 so that =Zw 13 2 ;
End while
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